5LH0 Stock Overview
A pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Guard Therapeutics International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.40 |
| 52 Week High | SEK 3.49 |
| 52 Week Low | SEK 0.25 |
| Beta | -0.076 |
| 11 Month Change | -4.00% |
| 3 Month Change | -21.05% |
| 1 Year Change | 860.00% |
| 33 Year Change | -70.62% |
| 5 Year Change | n/a |
| Change since IPO | -62.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5LH0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.4% | -1.9% | -2.6% |
| 1Y | 860.0% | -17.3% | 3.9% |
Return vs Industry: 5LH0 exceeded the German Biotechs industry which returned -17% over the past year.
Return vs Market: 5LH0 exceeded the German Market which returned 3.5% over the past year.
Price Volatility
| 5LH0 volatility | |
|---|---|
| 5LH0 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5LH0's share price has been volatile over the past 3 months.
Volatility Over Time: 5LH0's weekly volatility has decreased from 78% to 7% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 11 | Tobias Agervald | guardtherapeutics.com |
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019.
Guard Therapeutics International AB (publ) Fundamentals Summary
| 5LH0 fundamental statistics | |
|---|---|
| Market cap | €29.90m |
| Earnings (TTM) | -€6.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs 5LH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5LH0 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 78.82m |
| Earnings | -SEK 78.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5LH0 perform over the long term?
See historical performance and comparison